Menopausal Hormone Therapy

For a generation the Women's Health Initiative made menopausal hormone therapy look dangerous for everyone. The 2024–2026 evidence reads the same data as a timing, route, and formulation problem: started within about ten years of menopause, with the right estrogen route and progestogen, MHT is a well-supported treatment for symptoms and bone loss — though not a heart-disease or anti-aging drug.

Roughly two billion women will be postmenopausal by 2030 — meaning a sizeable fraction of the global population will spend a third to half their lifespan in profound estrogen deficiency.^[1] Ovarian failure is the earliest programmed organ-level senescence in the human body, and it drags cardiovascular, skeletal, neurological, and metabolic aging trajectories with it. Menopausal hormone therapy (MHT) is the only intervention that directly addresses that hormonal withdrawal. Whether it should be used as more than short-term symptom relief — in whom, with which molecule, by what route, and for how long — is the question the post-WHI literature has spent twenty years answering.

What menopause does, biologically

Menopause marks the terminal depletion of ovarian follicles and a permanent drop in circulating estradiol. Acute manifestations — hot flashes and night sweats (vasomotor symptoms, VMS), the genitourinary syndrome of menopause (GSM), sleep fragmentation, mood disturbance — are the visible top of the iceberg. The systemic consequences are larger: endothelial dysfunction, accelerated atherosclerosis, increased visceral adiposity, insulin resistance, accelerated bone resorption, ~0.5–1.5% annual loss of skeletal muscle mass, and faster epigenetic aging. Pooling four cohorts (n > 3,100), earlier menopause and bilateral oophorectomy both track with accelerated DNA-methylation age in blood, and a Mendelian-randomization analysis using menopause-associated variants points the causal arrow from menopause to epigenetic aging rather than the reverse.^[2] Age at menopause is itself prognostic: a meta-analysis of 32 studies in 310,329 women found menopause before age 45 carried about 50% higher risk of coronary heart disease (CHD) and roughly 12% higher all-cause mortality versus menopause at 45 or later.^[3]

Estrogen receptors (ERα and ERβ) sit on vascular endothelium, hippocampal and prefrontal neurons, osteoblasts, skeletal-muscle satellite cells, and the dermal matrix. Ovarian failure therefore isn't a reproductive event in isolation — it is the withdrawal of a master signaling molecule whose absence accelerates multiple hallmarks of aging simultaneously.

Two pharmacological branches exist:

Estrogen-only therapy (ET) — for women without a uterus.
Combined estrogen-progestogen therapy (EPT) — for women with an intact uterus; the progestogen exists solely to prevent endometrial hyperplasia from unopposed estrogen.^[4]

The risk-benefit calculus differs sharply between the two and depends on three further decisions: when therapy is started, how it is delivered, and which progestogen is paired with the estrogen.

The timing hypothesis (Moderate)

The single most consequential reframing of MHT since 2002 is the timing hypothesis — the cardiovascular effect of estrogen depends on whether the endothelium is still healthy enough to respond to it.

In healthy vasculature, estrogen upregulates endothelial nitric oxide synthase, inhibits vascular smooth-muscle proliferation, and slows atherosclerotic plaque formation. Initiated in this state, MHT preserves vascular function. In already-diseased vasculature, the same molecules can transiently destabilize advanced atherosclerotic plaques — by activating enzymes that break down the artery-wall matrix — and shift the prothrombotic / pro-inflammatory balance in the wrong direction.^[5]

The clinical translation:

Early initiation (<10 years post-menopause or age <60) — observational data show roughly 30–50% lower coronary heart disease incidence vs non-users, plus improved flow-mediated dilation (FMD, a marker of endothelial function).^[6] A meta-analysis of the randomized trials found MHT had no effect on all-cause mortality overall (relative risk 0.99), but in the subset of trials that started therapy early — mean age under 60 or within 10 years of menopause — mortality was about 30% lower (RR 0.70, 95% confidence interval 0.52–0.95).^[7] (A confidence interval is the range where the true effect most plausibly lies; when it stays below 1.0, as here, the benefit is unlikely to be chance.)
Late initiation (>10 years post-menopause or age >60) — no FMD improvement, elevated short-term risk of myocardial infarction (MI, heart attack), stroke, and venous thromboembolism (VTE), no offsetting cardioprotective benefit.^[8]

The WHI primary cohort had a mean age of 63 and a median time-since-menopause well over 10 years — exactly the population in which the timing hypothesis predicts harm. The original 2002 publications generalized that signal to all postmenopausal women, killing the field for two decades. Re-analyses stratified by age at initiation recover the early-initiation benefit.^[9] Two prospective trials — KEEPS (Kronos Early Estrogen Prevention Study) and ELITE (Early versus Late Intervention Trial with Estradiol) — tested the hypothesis directly, and both showed the predicted timing-dependent vascular response. But a caution the popular framing tends to drop: both were powered on surrogate endpoints (carotid-artery wall thickness, endothelial function), not hard cardiovascular events, and neither reduced heart attacks, strokes, or deaths. They validate the mechanism; they do not carry the coronary-incidence or mortality numbers, which come from the observational cohorts above. The 2024 twenty-year follow-up of the WHI reaches the parallel conclusion for prescribing: hormone therapy should not be used to prevent heart disease, stroke, dementia, or other chronic disease at any age, even as its benefit-to-risk profile is more favorable in women under 60 treating symptoms.^[10]

The 2025 guideline from the Korean Society of Menopause reaffirms this framework directly: starting standard-dose estrogen within 10 years of menopause or before age 60 is associated with reduced coronary artery disease (CAD) incidence and mortality — the guideline cites a roughly one-third reduction in CAD risk and an all-cause mortality reduction near 30% for early initiators — whereas the same therapy offers no benefit, and possibly harm, in women with established CAD.^[11]

Initiation timing	Endothelial response	Hard outcomes
<10 years post-menopause / age <60	Improved FMD, slowed atherogenesis, stable plaque	~30–50% CHD reduction; all-cause mortality reduction (RR ~0.70); fewer fractures
>10 years post-menopause / age >60	No FMD improvement; potential plaque destabilization	Elevated MI, stroke, VTE in the first 1–2 years of initiation

One line the modern guidelines draw firmly: cardiovascular prevention is not, on its own, an indication for MHT. The timing-hypothesis benefit is a favorable side effect of treating something else, not a licence to prescribe hormones to prevent heart disease. The genuine first-line indications remain vasomotor symptoms, the genitourinary syndrome (best addressed with low-dose vaginal estrogen), and early postmenopausal bone loss — and even the cardiovascular association is graded only Moderate, weighed down by the healthy-user bias that runs through the observational data.

Route matters: oral vs transdermal (Strong)

Estrogen route changes the drug. Oral estrogens pass through the liver before reaching the systemic circulation; the hepatic first-pass triggers synthesis of clotting factors, raises C-reactive protein (CRP, a marker of inflammation), and elevates triglycerides. Transdermal estradiol (patch, gel, spray) bypasses the liver entirely and reaches tissue through systemic microcirculation, mimicking ovarian secretion.

The hard outcome difference is clean: oral estrogen carries a real signal for VTE and ischemic stroke; transdermal estradiol does not raise either above baseline.^[12] Society guidelines uniformly recommend transdermal as the preferred route in women with cardiometabolic risk, obesity, prior VTE, smoking history, migraine with aura, or factor V Leiden.^[13]

Transdermal also avoids the oral-estrogen rise in triglycerides and CRP — relevant for any patient with metabolic syndrome.

The progestogen question (Strong)

The breast cancer signal that drove the 2002 WHI panic was almost entirely a progestogen signal, not an estrogen signal. Two strands of evidence carry that conclusion.

ET-only post-hysterectomy is breast-neutral, possibly protective. Extended follow-up of the WHI estrogen-alone arm showed lower invasive breast cancer incidence and lower breast cancer mortality on conjugated equine estrogens (CEE) vs placebo.^[14] A plausible mechanism: breast cells adapted to a chronic low-estrogen environment can undergo apoptosis on reintroduction.

Within EPT, the choice of progestogen is the dominant variable. A 2026 systematic review confirms that synthetic progestins — particularly medroxyprogesterone acetate (MPA) and norethisterone — drive the breast cancer signal seen in older trials.^[15] Natural micronized progesterone ("body-identical") and the retroprogesterone dydrogesterone show neutral-to-negligible breast risk at standard treatment durations. The cleanest single dataset is the French E3N cohort — 80,377 postmenopausal women, 2,354 invasive breast cancers over a mean 8.1 postmenopausal years — in which, relative to never-use, breast cancer risk was essentially unchanged with estrogen plus micronized progesterone (1.00, 95% CI 0.83–1.22), a non-significant 16% higher with estrogen plus dydrogesterone (1.16, 0.94–1.43 — the interval crosses 1.0, so compatible with no effect), and a clear 69% higher with estrogen combined with other progestogens (1.69, 1.50–1.91). Route of estrogen made no difference; the progestogen did.^[16]

Progestogen	Classification	Breast cancer signal	Current standing
Medroxyprogesterone acetate	Synthetic	Elevated; the driver of the WHI breast signal	Largely deprecated in modern practice
Norethisterone	Synthetic	Elevated	Used selectively; avoided when breast risk is prioritized
Micronized progesterone	Body-identical	Neutral / negligible at standard durations	First-line for endometrial protection; also improves sleep
Dydrogesterone	Retroprogesterone	Neutral / negligible	Comparable safety to micronized progesterone where available

The modern gold standard for a woman with an intact uterus is transdermal estradiol plus oral micronized progesterone — minimizing thrombotic and breast risks simultaneously.^[17]

Cardiometabolic effects (Strong)

The menopausal transition redistributes adipose tissue centrally, reduces lean mass, and raises the risk of metabolic syndrome — and the earlier the transition, the worse the downstream cardiometabolic trajectory.^[18] MHT initiated in the early window blunts visceral fat accumulation and improves glucose homeostasis, on pathways that overlap with the metabolic-rescue mechanisms identified by other geroprotector classes (GLP-1, geroprotectors).

The Wilder pattern repeats — the rule that a treatment helps roughly in proportion to how far the patient has already drifted from a healthy baseline. The cardiometabolic benefit concentrates in women whose risk has begun to move in the wrong direction. In a metabolically healthy 50-year-old, MHT's net cardiometabolic effect is modest. In one with rising visceral adiposity, deteriorating insulin sensitivity, or worsening lipids, the effect is large.

Bones — and the post-cessation rebound (Strong)

MHT is among the most effective osteoporosis-prevention interventions available. The largest analysis to date — a UK primary-care nested case-control study matching 648,747 women with a first fracture to 2,357,125 fracture-free controls — found roughly a 25% reduction in fracture odds during current use (estrogen-only OR 0.76, 95% CI 0.74–0.78; estrogen-progestogen OR 0.75, 0.73–0.76).^[19]

The discontinuation trajectory is the part that matters clinically. Protection does not persist smoothly: in the 1–10 years after stopping, fracture odds climb back to — and for estrogen-progestogen slightly above — never-user levels (OR 1.06, 1.05–1.08), an excess concentrated in women who used MHT for under 5 years and equivalent to roughly 14 extra fractures per 10,000 woman-years. Beyond 10 years post-cessation the odds fall below never-use again (OR 0.93–0.95). The microarchitectural gains banked during treatment do translate into a durable long-run benefit — but the cessation window itself is a real vulnerability requiring either a slow taper or bridging anti-resorptive therapy. See bone density for the LIFTMOR-style resistance protocol that complements MHT.

Muscle and physical vitality (Moderate)

Estrogen receptors on skeletal muscle directly modulate protein synthesis, satellite-cell activation, and oxidative-stress buffering. After menopause, women lose ~0.5–1.5% of skeletal muscle mass per year attributable to estrogen withdrawal — on top of generic age-related sarcopenia.

A 2025 meta-analysis of 15 RCTs (n>2,400) found MHT — typically combined with structured nutritional and exercise protocols — produced:

Skeletal muscle mass index: +0.22 kg/m²
Handgrip strength: +1.77 kg
Gait speed: +0.09 m/s

^[20]

A separate 2025 cross-sectional analysis showed physical inactivity during the transition is the single strongest predictor of functional decline — nearly four times the odds of slow gait speed in inactive vs active women (odds ratio 3.93), with type 2 diabetes and obesity multiplying the sarcopenia risk independently.^[21] The structural lesson is the same as on every other clinical pillar: MHT is a scaffold, not a substitute for resistance training and adequate protein.

Brain: cognition, mood, sleep (Moderate)

The neurology version of the timing hypothesis is the cleanest. The 2002 WHI Memory Study (WHIMS) famously doubled all-cause dementia risk when oral CEE plus MPA was initiated in women over 65 — a finding that defined a generation of geriatric prescribing.^[22]

Two prospective trials in early initiators tell a very different story:

KEEPS — 4 years of transdermal or oral estrogen started within 3 years of menopause. The 10-year follow-up imaging cohort used PET for amyloid and tau plus formal cognitive batteries: no long-term adverse cognitive effects vs placebo, and no protective benefit either.^[23]
ELITE — confirmed the timing-stratified vascular response, with neutral cognitive findings in early initiators.^[24]

The honest summary: MHT initiated early does not harm long-term cognition; it does not, on current evidence, independently preserve it either. The exception is premature menopause — surgical or natural ovarian failure before age 45, where prolonged hypoestrogenism is itself a dementia risk factor and immediate hormonal replacement is indicated.^[25]

Mood and sleep are where MHT delivers fast, large, consistently measurable benefit. The European Society of Endocrinology (ESE) explicitly recognizes perimenopause as an independent risk factor for depressive symptoms and notes MHT effective for the transition-associated mood disturbance specifically.^[26] Long-term observational data show roughly 30% better sleep-quality scores (on the Pittsburgh Sleep Quality Index) sustained over years in MHT users — see insomnia treatment, and screen for sleep-disordered breathing before attributing all sleep symptoms to menopause.^[27]

Other cancers (Moderate)

Ovarian cancer. Long-duration MHT (>5–10 years) is associated with a small absolute increase in ovarian cancer risk — roughly one additional death per 1,700–3,300 users for 5 years' use starting around age 50, predominantly in the serous and endometrioid subtypes.^[28] The risk dissipates back to population baseline within ~5 years of stopping. In women with an existing epithelial ovarian cancer diagnosis, MHT for symptom control does not adversely affect recurrence or survival.

Endometrial cancer. Adequately dosed continuous progestogen completely neutralizes the endometrial hyperplasia and carcinoma risk that unopposed estrogen would otherwise cause. This is the entire reason EPT exists.

Colorectal cancer. Observational signals are modestly inverse (suggesting protection), but the randomized evidence is mixed; the effect, if real, is small.

Epigenetic biomarkers of aging (Weak / preliminary)

The menopausal transition accelerates DNA methylation–based aging measured by second-generation epigenetic clocks (PhenoAge, GrimAge), which were trained on clinical biomarkers and mortality data rather than chronological age and outperform first-generation clocks (Horvath, Hannum) in predicting age-related disease and all-cause mortality.^[29] The mechanistic argument that MHT decelerates this acceleration is plausible — estrogen preserves telomerase activity, dampens oxidative stress, and maintains mitochondrial DNA copy number — but the direct RCT evidence that MHT slows specific epigenetic clocks in healthy adult women is still preliminary; large longitudinal cohorts are running.

For now, treat this as a mechanism-rich, hard-outcome-pending claim — similar to where rapamycin and metformin sit on the geroprotector ladder.

Estetrol — a next-generation estrogen (Emerging)

Estetrol (E4) is a naturally occurring fetal estrogen produced exclusively by the human fetal liver during pregnancy. It belongs to a new pharmacological class — Native Estrogen with Selective action in Tissues (NEST) — meaning it acts as a full agonist in brain, bone, and vaginal tissue while remaining neutral or antagonistic in breast tissue and hepatic coagulation pathways.^[30]

The phase 3 E4COMFORT I trial randomised 640 postmenopausal women aged 40–65 to estetrol 15 mg, estetrol 20 mg, or placebo for 12 weeks:^[31]

Both doses significantly reduced the weekly frequency and the severity of moderate-to-severe vasomotor symptoms at weeks 4 and 12 versus placebo; 15 mg was the lower of the two effective doses.
Drug-related adverse events occurred in 51.6% (15 mg), 57.3% (20 mg), and 20.6% (placebo), with discontinuation for adverse events in 6.6%, 7.5%, and 2.3% respectively — few women stopped the drug, but it is not side-effect free.

Separate analyses across the estetrol development program report minimal triglyceride change, improved glucose tolerance at higher doses, decreased bone-resorption marker CTX-1, and no clinically meaningful change in blood pressure even in women with pre-existing cardiovascular risk factors — though the blood-pressure data were presented at a 2025 conference and are not yet peer-reviewed.^[32] Multi-decade thrombotic safety data in postmenopausal women are still pending, but the NEST mechanism is the most promising effort in years to deliver oral estrogen with a transdermal-like safety profile.

Non-hormonal alternatives (Moderate)

For women with hard contraindications to estrogen — hormone-receptor-positive breast cancer history, active thromboembolic disease, unexplained vaginal bleeding, severe uncontrolled cardiovascular disease — the modern non-hormonal options have moved well beyond selective serotonin reuptake inhibitors (SSRIs).

Neurokinin 3 receptor (NK3R) antagonists (fezolinetant, elinzanetant) act on the hypothalamic temperature-control neurons that trigger hot flashes. They reduce VMS frequency and severity by 50–65% with no hormonal exposure.^[33]

SSRIs and SNRIs (serotonin-norepinephrine reuptake inhibitors) — paroxetine, escitalopram, venlafaxine — deliver 40–60% VMS reduction plus mood benefit; the magnitude is smaller than MHT but consequential in patients who can't take estrogen.

Mind-body therapies earned a stronger evidence base than many clinicians realize. A 2025 systematic review and meta-analysis of RCTs in >1,500 menopausal women found that mind-body interventions (yoga, mindfulness, qigong, music, dance) significantly improved sleep quality, depression, and anxiety — all large effects (standardized mean differences of −0.86, −0.79, and −1.13, where roughly −0.8 counts as large).^[34] These effect sizes are larger than for most pharmacological mood interventions in the same population, though the trials are small and short.

Skin and the genitourinary syndrome (Moderate for skin; Strong for the genitourinary syndrome)

Estrogen drives synthesis and turnover of dermal collagen, elastin, and hyaluronic acid. Postmenopausal hypoestrogenism produces dryness, thinning, wrinkling, and epidermal barrier degradation. A meta-analysis of MHT trials reports large dermatological effect sizes — for dermal collagen content a standardized mean difference of 2.01, and for skin elasticity 1.27 (both well above the ~0.8 "large" threshold, though from small trials).^[35]

For the genitourinary syndrome (vaginal dryness, dyspareunia, recurrent UTIs, overactive bladder), local low-dose vaginal estrogen and intravaginal DHEA (dehydroepiandrosterone; sold as prasterone) are the highest-leverage interventions in all of menopausal medicine. In the placebo-controlled registration trial of daily intravaginal prasterone 6.5 mg, 12 weeks of treatment significantly improved vaginal cell maturation, lowered vaginal pH, and reduced the severity of dyspareunia and dryness versus placebo.^[36] Histology series report restored epithelial thickness plus increased elastin and nerve-ending density in the lamina propria, though those are small uncontrolled samples and the widely quoted percentage gains in nerve-fibre density do not come from a controlled trial. Systemic absorption is minimal; the safety profile is permissive even in many women with contraindications to systemic MHT, including selected breast-cancer survivors with oncology co-management.

All-cause mortality and continuation beyond age 65 (Moderate)

A nationwide Danish register-based cohort of more than 800,000 women (over 104,000 MHT users) followed through 2023 found no increase in all-cause mortality — in fact a small reduction (adjusted hazard ratio 0.96), concentrated in mid-duration users.^[37] That aligns with the trial meta-analysis above, where the early-initiation subgroup showed roughly 30% lower mortality (RR 0.70) even though MHT overall was mortality-neutral. The 2024 update of the NICE menopause guideline reaches the same conclusion — combined HRT does not raise cardiovascular or overall mortality.^[38] The important caveat: this registry cohort was born between 1950 and 1977, so most participants were still only in their fifties at the close of follow-up — the mortality window is too early for a definitive lifetime conclusion, and the effect grade here is best read as Moderate rather than settled. Extended follow-up of the WHI estrogen-alone arm showed reductions in long-term mortality, including breast cancer and Alzheimer's disease mortality specifically.^[39]

Larger and more dramatic figures circulate — a 2025 Menopause Society conference presentation on more than 120 million health records was widely reported as showing roughly 60% lower odds of breast cancer, heart attack, or stroke in long-term early initiators. That analysis has not been peer-reviewed or published, so it is not treated as evidence here. Healthy-user bias in particular pervades this literature: women prescribed and retained on MHT tend to be healthier, wealthier, and more engaged with preventive care than never-users, and no amount of adjustment removes that.

Use after age 65. Up to 40% of women in their 60s and ~15% in their 70s still experience hot flashes; a 2024 retrospective analysis of women over 65 on MHT (mean age 71, some over 80) found 87% of those who attempted to stop had severe symptom recurrence and resumed therapy.^[40] The Menopause Society's current position is explicit: there is no universal age limit for continuation, provided lower-dose transdermal regimens are used and surveillance is active.^[41] Initiation after 65 is a different and riskier proposition than continuation of long-established therapy.

Diagnostic and monitoring framework (Strong on protocol)

Before initiation:

History. Age at menopause, time since final menstrual period; personal and family history of breast, ovarian, and endometrial cancer; prior VTE, stroke, CHD, migraine with aura, liver disease; known prothrombotic mutations (factor V Leiden).
Examination. Blood pressure, breast and pelvic exam, BMI and waist circumference.
Laboratory. Lipid panel including apoB (apolipoprotein B, the count of atherogenic particles); HbA1c and fasting glucose; liver and renal function; thyroid-stimulating hormone (TSH). Follicle-stimulating hormone (FSH) and estradiol only when diagnosis is uncertain (e.g., perimenopausal symptoms with retained cycles).
Imaging. Mammography per age-appropriate cadence; a DXA (dual-energy X-ray absorptiometry) bone-density scan in any woman with risk factors for early bone loss; pelvic ultrasound if abnormal bleeding.

Formulation choice:

Component	Preferred	Acceptable alternative	Avoid where possible
Estrogen	Transdermal estradiol (patch, gel, spray)	Oral estradiol in low cardiometabolic risk	Conjugated equine estrogens (largely historical)
Progestogen (intact uterus)	Oral micronized progesterone 100–200 mg	Dydrogesterone	MPA, norethisterone
Local GSM	Vaginal estrogen, intravaginal DHEA (prasterone)	Non-hormonal moisturizers	—
Emerging oral	Estetrol 15 mg + micronized progesterone	—	—

Targets and follow-up:

Lowest effective dose for symptom control; titrate downward over time as tolerated.
Recheck symptoms, BP, and weight at 3 months, then every 6–12 months.
Annual breast exam plus mammography per age-based cadence; DXA every 2–3 years if at risk.
No mandatory stop date. Annual shared-decision review of continuation, with documented assessment of ongoing benefit vs incremental risk.

What's overrated

The WHI-era "all hormone therapy is dangerous" frame. Generalizing oral CEE plus MPA in women a decade past menopause to transdermal estradiol plus micronized progesterone in a 51-year-old is a categorical error. The modern literature has done the disaggregation; the cultural memory hasn't caught up.
MHT as primary cognitive prevention. KEEPS Continuation is honest about this — no harm, no independent benefit, when started early. The levers that actually move dementia risk — hearing aids, blood pressure control, exercise, sleep — outperform on absolute terms (dementia prevention).
Compounded "bioidentical" hormone cocktails. "Body-identical" estradiol and micronized progesterone are available as licensed, regulated, evidence-based products. The compounded pellet / cream / lozenge industry adds dose variability, lacks endometrial-protection guarantees, and circulates a marketing claim that doesn't survive contact with the pharmacology.
Stopping at an arbitrary age. There is no evidence-based age cutoff for continuation in a stable, symptom-driven regimen under active surveillance.

Cautions

Late initiation in the late-60s and beyond. Increased short-term MI, stroke, and VTE risk in the first 1–2 years. Initiation after 60–65 needs unambiguous indication and full informed consent; this is not the same as continuing existing therapy.
Oral estrogen in cardiometabolic risk. Hepatic first-pass raises clotting factor synthesis, CRP, and triglycerides. Use transdermal in obesity, prior VTE, smoking, migraine with aura, or hypertriglyceridemia.
Synthetic progestins. MPA and norethisterone carry a meaningful breast cancer signal vs micronized progesterone or dydrogesterone; the modern default should be the latter.
Long-duration MHT and ovarian cancer. Small but real absolute increase with >5–10 years of use; revisit the indication annually.
Hard contraindications. Personal history of hormone-receptor-positive breast cancer, active estrogen-dependent malignancy, active thromboembolic disease, unexplained vaginal bleeding, severe uncontrolled cardiovascular disease, severe active liver disease.
The Wilder asymmetry. As with TRT and GLP-1s, the biggest absolute benefits concentrate in women whose underlying trajectory has begun to deteriorate. In a perfectly healthy 50-year-old without symptoms, the net longevity case is more modest than enthusiastic communicators suggest.